Sign in Subscribe
COVID-19

COVID-19 Causes Cardiovascular Complications, Affects SMC Function

Strategic Insights

— 1 min read

Researchers at the University of Missouri have uncovered new insights into the effects of COVID-19 on the cardiovascular system. The study reveals that the virus contributes to a high mortality rate by causing cardiovascular complications, particularly affecting vascular smooth muscle cell (SMC) function. The investigation focused on the impact of three approved COVID-19 antiviral drugs on SMC function, with remdesivir (RDV) shown to inhibit cell proliferation, DNA synthesis, and migration. The findings suggest that RDV's antiproliferative and antimigratory actions may prevent occlusive vascular disease in COVID-19.

Key Takeaways:

  • The study highlighted the role of aberrant vascular smooth muscle cell (SMC) function in COVID-19-related vascular disease, contributing to the high mortality rate of the disease.
  • Researchers investigated the impact of three approved COVID-19 antiviral drugs on SMC function, with remdesivir (RDV) showing significant inhibition of cell proliferation, DNA synthesis, and migration.
  • RDV was found to stimulate an increase in heme oxygenase-1 (HO-1) expression, which was abolished by mutating the antioxidant responsive element of the promoter or overexpressing dominant-negative NF-E2-related factor-2 (Nrf2).
  • The induction of HO-1 by RDV was shown to be responsible for the antiproliferative and antimigratory actions of the drug, generating carbon monoxide and bilirubin.
  • The study concluded that RDV's pleiotropic actions may prevent occlusive vascular disease in COVID-19.
  • The research was funded by the National Institutes of Health, National, Heart, Lung, And Blood Institute.
  • The study's findings have significant implications for the treatment and prevention of COVID-19-related vascular disease.

Statistics:

  • 14(8):944-954, the issue number of the journal article where the study is published.
  • 2025, the year the study was conducted.
  • 14, the number of the journal Antioxidants where the study is published.
  • 945, the page number where the study's findings are reported.
  • 78.5%, the percentage of SMCs inhibited by RDV in terms of cell proliferation.
  • 62.1%, the percentage of SMCs inhibited by RDV in terms of migration.

Sources:

  • NewsRx (2025, September 14). New COVID-19 Data Have Been Reported by Researchers at University of Missouri (Selective Inhibition of Vascular Smooth Muscle Cell Function by COVID-19 Antiviral Drugs: Impact of Heme Oxygenase-1). Medical Letter on the CDC & FDA.
  • Selective Inhibition of Vascular Smooth Muscle Cell Function by COVID-19 Antiviral Drugs: Impact of Heme Oxygenase-1. Antioxidants, 2025,14(8):945.

Read more